NovoCure's Operating Income fell 1224.29% to -$36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.7 million, marking a year-over-year decrease of 1120.33%. This contributed to the annual value of -$170.5 million for FY2024, which is 2678.49% up from last year.
As of Q3 2025, NovoCure's Operating Income stood at -$36.0 million, which was down 1224.29% from -$39.5 million recorded in Q2 2025.
NovoCure's Operating Income's 5-year high stood at -$88000.0 during Q1 2021, with a 5-year trough of -$63.3 million in Q4 2024.
Over the past 5 years, NovoCure's median Operating Income value was -$36.0 million (recorded in 2025), while the average stood at -$34.2 million.
Per our database at Business Quant, NovoCure's Operating Income surged by 9739.72% in 2021 and then plummeted by 737506.2% in 2023.
Quarter analysis of 5 years shows NovoCure's Operating Income stood at -$23.4 million in 2021, then tumbled by 83.68% to -$43.0 million in 2022, then fell by 20.33% to -$51.7 million in 2023, then dropped by 22.41% to -$63.3 million in 2024, then skyrocketed by 43.1% to -$36.0 million in 2025.
Its Operating Income stands at -$36.0 million for Q3 2025, versus -$39.5 million for Q2 2025 and -$37.9 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value